212
Participants
Start Date
February 5, 2019
Primary Completion Date
June 29, 2023
Study Completion Date
June 29, 2023
acapatamab
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
Pembrolizumab
Combined with acapatamab for investigational treatment of mCRPC
Etanercept
Prophylaxis for acapatamab-related cytokine release syndrome.
Cytochrome P450 (CYP) Cocktail
Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
Krankenhaus der Barmherzigen Brueder Wien, Vienna
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna
Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Brussels
Scientia Clinical Research Ltd, Randwick
Chris OBrien Lifehouse, Camperdown
Peter MacCallum Cancer Centre, Parkville
Ordensklinikum Linz Elisabethinen, Linz
Landeskrankenhaus Salzburg, Salzburg
Universitair Ziekenhuis Gent, Ghent
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College, New York
Emory University, Atlanta
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan District
Indiana University, Indianapolis
University of Iowa Hospitals and Clinics, Iowa City
Washington University, St Louis
Tulane Medical Center, New Orleans
University of Texas Southwestern Medical Center, Dallas
Comprehensive Cancer Centers of Nevada, Las Vegas
University of California Los Angeles, Los Angeles
City of Hope at Long Beach Elm, Long Beach
City of Hope National Medical Center, Duarte
Institut Gustave Roussy, Villejuif
El Camino Hospital, Campbell
National University Hospital, Singapore
National Cancer Centre Singapore, Singapore
BC Cancer Vancouver, Vancouver
National Cancer Center Hospital East, Kashiwa-shi
Yokohama City University Medical Center, Yokohama
Erasmus Medisch Centrum, Rotterdam
Lead Sponsor
Amgen
INDUSTRY